Allergy Therapeutics
An international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease.
The group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut.
Latest Allergy Therapeutics News & Features
13 December 2023
14 November 2023
16 October 2023
13 September 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze